Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial

Rajeka Lazarus, Christian Taucher, Claire Brown, Irena Corbic, Leon Danon, Katrin Dubischar, Christopher J.A. Duncan, Susanne Eder-Lingelbach, Saul N Faust, Christopher Green, Karishma Gokani, Romana Hochreiter, Johanna Kellett Wright, Dowan Kwon, Alexander Middleditch, Alasdair P.S. Munro, Kush Naker, Florentina Penciu, David Price, Benedicte Querton, Tawassal Riaz, Amy Ross-Russell, Amada Sanchez-Gonzalez, Hayley Wardle, Sarah Warren, Adam Finn, the Valneva Phase 1 Trial Group
doi: https://doi.org/10.1101/2021.08.13.21262021
Rajeka Lazarus
1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
DPhil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Taucher
2VALNEVA AUSTRIA GMBH, Vienna, Austria
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christian.taucher{at}valneva.com
Claire Brown
3NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irena Corbic
2VALNEVA AUSTRIA GMBH, Vienna, Austria
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leon Danon
4Department of Engineering Mathematics, University of Bristol, Bristol, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrin Dubischar
2VALNEVA AUSTRIA GMBH, Vienna, Austria
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J.A. Duncan
5Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust; Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle, UK
DPhil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne Eder-Lingelbach
2VALNEVA AUSTRIA GMBH, Vienna, Austria
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saul N Faust
6NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; and Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Green
3NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
DPhil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karishma Gokani
3NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romana Hochreiter
2VALNEVA AUSTRIA GMBH, Vienna, Austria
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna Kellett Wright
1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dowan Kwon
1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Middleditch
1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
FFICM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alasdair P.S. Munro
6NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; and Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK
MRCPCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kush Naker
3NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florentina Penciu
1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Price
5Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust; Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benedicte Querton
2VALNEVA AUSTRIA GMBH, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tawassal Riaz
1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Ross-Russell
MRCP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amada Sanchez-Gonzalez
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hayley Wardle
MB ChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Warren
6NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; and Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK
MBBS, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Finn
1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
7Schools of Population Health Sciences and Cellular and Molecular Medicine, University of Bristol, Bristol UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background We assessed the safety, tolerability and immunogenicity of VLA2001 is a whole-virion inactivated SARS-CoV-2 vaccine adsorbed to alum with a toll-like receptor 9 agonist adjuvant in healthy volunteers aged 18-55.

Methods The first 15 participants were enrolled, in groups of 5, to receive two doses, separated by 21 days, of one of three dose concentrations, administered intramuscularly. 138 further participants were randomised 1:1:1 to receive the same 3 dose concentrations, in a double blinded manner. Primary outcomes were solicited adverse reactions 7 days after each vaccination and neutralising antibody geometric mean titres (GMT) against SARS-CoV-2, 2 weeks after the second vaccination (day 36), measured by live microneutralisation assay against wild-type virus (MNA50). Secondary outcomes included unsolicited adverse events, and humoral and cellular responses at day 36, measured by IgG ELISA against Spike protein and interferon-γ secreting T-cells by ELISpot stimulated with multiple SARS-CoV-2 antigens. (ClinicalTrials.gov NCT04671017, ISRCTN 82411169)

Findings Between December 16, 2020 and January 21, 2021, 153 participants were enrolled and randomised evenly between the dose groups. The rates of solicited reactions were similar after the first and second doses and between the three dose groups. The most frequent local reactions were tenderness (58·2%) and pain (41·8%) and systemic reactions were headache (46%) and fatigue (39·2%).

In the high dose group, two weeks following the second dose, the geometric mean titres were 530.4 (95% CI: 421·49, 667·52) for neutralizing antibodies and 2147·9 (95% CI: 1705·98, 2704·22) for S-binding antibodies. There was a dose dependent response with 90·0% (95% CI:78·0%.,97·0%) seroconversion (4-fold rise) at day 36 in the high dose group, which was significantly higher than rates in both the medium (73.5%; 95% CI: 59%,85%), CIs) and low dose (51%; 95%CI: 37%,65%) rate, CIs) groups (both p < 0.001). Antigen-specific interferon-γ T-cells reactive against the S, M and N proteins were observed in 76, 36 and 49% of high dose recipients, respectively.

Interpretation VLA2001-201 was well tolerated and produced both humoral and cellular immune responses, with a clear dose-response effect.

Funding This study was funded by the Department of Health and Social Care, UK

The funder had no role in the study design, implementation or analysis.

Competing Interest Statement

CT, BQ, KD, SE-L and RH are all employees of Valneva. RL has worked on trials funded by Aztra Zeneca and Janssen but receives no personal financial payment for this work. AF is a member of the Joint Committee on Vaccination and Immunisation and Chair of the WHO European Technical Advisory Group of Experts (ETAGE) on Immunisation. He is an investigator and/or provides consultative advice on clinical trials and studies of COVID-19 vaccines produced by AstraZeneca, Janssen, Valneva, Pfizer and Sanofi and of other vaccines from these and other manufacturers including GSK, VPI, Takeda and Bionet Asia. He receives no personal remuneration or benefits for any of this work. SNF acts on behalf of University Hospital Southampton NHS Foundation Trust as an Investigator and/or providing consultative advice on clinical trials and studies of COVID-19 and other vaccines funded or sponsored by vaccine manufacturers including Janssen, Pfizer, AstraZeneca, GlaxoSmithKline, Novavax, Seqirus, Sanofi, Medimmune, Merck and Valneva vaccines and antimicrobials. He receives no personal financial payment for this work.

Clinical Trial

ClinicalTrials.gov NCT04671017

Funding Statement

This study was funded by the Department of Health and Social Care, UK The funder had no role in the study design, implementation or analysis

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved in the UK by the Medicines and Healthcare products Regulatory Agency (43185/0002/001-0001) and the London, Brent ethics committee ref 20/HRA/5205.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The seroconversion rates given in the results section were incorrect. The correct rates were in the abstract so the this has been amended.

Data Availability

Data available on request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 20, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial
Rajeka Lazarus, Christian Taucher, Claire Brown, Irena Corbic, Leon Danon, Katrin Dubischar, Christopher J.A. Duncan, Susanne Eder-Lingelbach, Saul N Faust, Christopher Green, Karishma Gokani, Romana Hochreiter, Johanna Kellett Wright, Dowan Kwon, Alexander Middleditch, Alasdair P.S. Munro, Kush Naker, Florentina Penciu, David Price, Benedicte Querton, Tawassal Riaz, Amy Ross-Russell, Amada Sanchez-Gonzalez, Hayley Wardle, Sarah Warren, Adam Finn, the Valneva Phase 1 Trial Group
medRxiv 2021.08.13.21262021; doi: https://doi.org/10.1101/2021.08.13.21262021
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial
Rajeka Lazarus, Christian Taucher, Claire Brown, Irena Corbic, Leon Danon, Katrin Dubischar, Christopher J.A. Duncan, Susanne Eder-Lingelbach, Saul N Faust, Christopher Green, Karishma Gokani, Romana Hochreiter, Johanna Kellett Wright, Dowan Kwon, Alexander Middleditch, Alasdair P.S. Munro, Kush Naker, Florentina Penciu, David Price, Benedicte Querton, Tawassal Riaz, Amy Ross-Russell, Amada Sanchez-Gonzalez, Hayley Wardle, Sarah Warren, Adam Finn, the Valneva Phase 1 Trial Group
medRxiv 2021.08.13.21262021; doi: https://doi.org/10.1101/2021.08.13.21262021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3298)
  • Dentistry and Oral Medicine (365)
  • Dermatology (280)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1173)
  • Epidemiology (13384)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5157)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3274)
  • Health Policy (1143)
  • Health Systems and Quality Improvement (1193)
  • Hematology (432)
  • HIV/AIDS (1019)
  • Infectious Diseases (except HIV/AIDS) (14636)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (478)
  • Medical Ethics (127)
  • Nephrology (525)
  • Neurology (4930)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (886)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (727)
  • Orthopedics (282)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (544)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4218)
  • Public and Global Health (7511)
  • Radiology and Imaging (1708)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (424)
  • Surgery (549)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)